The results verify conclusions drawn by Bagli et al. [one], who conducted a research that bundled ten patients diagnosed with CRAO who received HBOT. As well as receiving 20 classes of HBOT, oral acetazolamide and topical beta-blockers were administered to the patients for the earliest attainable time.Our turnkey support options involve training, a